R-metHuLeptin ( DrugBank: r-metHuLeptin )
1 disease
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
265 | Lipodystrophy | 1 |
265. Lipodystrophy
Clinical trials : 116 / Drugs : 170 - (DrugBank : 61) / Drug target genes : 26 - Drug target pathways : 97
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00140244 (ClinicalTrials.gov) | December 2001 | 30/8/2005 | Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome | Role of Leptin in Highly Active Antiretroviral Therapy (HAART)-Induced Lipodystrophy and Metabolic Syndrome in HAART-Treated HIV Patients | HAART-induced Lipodystrophy and Metabolic Syndrome | Drug: r-metHuLeptin;Drug: Placebo | Beth Israel Deaconess Medical Center | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);Amgen | Completed | 18 Years | N/A | All | 7 | Phase 2 | United States |